Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well savolitinib works in treating patients with MET
amplified colorectal cancer that has spread to other places in the body (metastatic) or
cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.